SARS-CoV-2 may pose an occupational health risk to healthcare workers. Here, we report
the seroprevalence of SARS-CoV-2 antibodies, self-reported symptoms and occupational …

Background Stroke has transitioned from an untreatable, unpreventable disease to a highly
treatable and preventable disease over recent decades, and the number of stroke survivors …

Background and Aims Patients with severe coronavirus disease 2019 (COVID‐19) are at
significant risk of thrombotic complications. However, their prothrombotic state is incompletely …

The main entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
is angiotensin‐converting enzyme 2 (ACE2). SARS‐CoV‐2 interactions with ACE2 may …

Current SARS-CoV-2 serological assays generate discrepant results, and the longitudinal
characteristics of antibodies targeting various antigens after asymptomatic to mild COVID-19 …

Objective To determine whether fluoxetine, at any dose, given within the first year after stroke
to patients who did not have to have mood disorders at randomization reduced disability, …

Background The effect of alteplase on patient survival after ischaemic stroke is the subject
of debate. We report the effect of intravenous alteplase on long-term survival after ischaemic …

Background Small trials have suggested that fluoxetine may improve neurological recovery
from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, …

Introduction Information about the impact of functional outcome after stroke is currently missing
on health-related quality of life, survival and costs. This information would be valuable for …

Background Elevated plasma levels of troponin in acute stroke patients are common and
have in several studies been shown to predict in-hospital and short-term mortality. Little is, …